Literature DB >> 33891996

Examining the gut-liver axis in liver cancer using organoid models.

Dmitrii Shek1, Dishen Chen2, Scott A Read3, Golo Ahlenstiel4.   

Abstract

The World Health Organization predicts that by 2030 liver cancer will cause 1 million deaths annually, thus becoming the third most lethal cancer worldwide. Hepatocellular carcinoma and cholangiocarcinoma are the two major primary cancer subtypes involving the liver. Both are often diagnosed late, and hence response to treatment and survival are poor. It is therefore of utmost importance to understand the mechanisms by which liver cancers initiate and progress. The causes of primary liver cancer are diverse, resulting primarily from obesity, chronic alcohol abuse or viral hepatitis. Importantly, both alcohol and high fat diet can promote intestinal permeability, enabling microbial translocation from the gut into the liver. As a result, these microbial antigens and metabolites exacerbate hepatic inflammation and fibrosis, increasing the risk of primary liver cancer. Organoids are primary, three-dimensional, stem cell derived liver models that can recapitulate many of the disease phenotypes observed in vivo. This review aims to summarize the advantages of organoid culture to examine the gut-liver axis with respect to cancer initiation and progression. In particular, the use of gut and liver organoid mono- and co-cultures together and with immune cell populations to best recapitulate disease mechanisms and develop therapeutic interventions.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alcoholic liver disease; Cirrhosis; Fibrosis; Intestinal permeability; MAFLD; NASH

Mesh:

Year:  2021        PMID: 33891996     DOI: 10.1016/j.canlet.2021.04.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

Review 1.  Organoids in recapitulating tumorigenesis driven by risk factors: Current trends and future perspectives.

Authors:  Jie Zhang; Lei Wang; Qianqian Song; Mingbing Xiao; Jie Gao; Xiaolei Cao; Wenjie Zheng
Journal:  Int J Biol Sci       Date:  2022-03-28       Impact factor: 10.750

Review 2.  Tumor organoids: applications in cancer modeling and potentials in precision medicine.

Authors:  Hanxiao Xu; Dechao Jiao; Aiguo Liu; Kongming Wu
Journal:  J Hematol Oncol       Date:  2022-05-12       Impact factor: 23.168

Review 3.  Urological cancer organoids, patients' avatars for precision medicine: past, present and future.

Authors:  Haotian Chen; Wentao Zhang; Niraj Maskey; Fuhan Yang; Zongtai Zheng; Cheng Li; Ruiliang Wang; Pengfei Wu; Shiyu Mao; Junfeng Zhang; Yang Yan; Wei Li; Xudong Yao
Journal:  Cell Biosci       Date:  2022-08-19       Impact factor: 9.584

4.  Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells.

Authors:  Jingliang Wu; Cuiping Qi; Hao Wang; Qing Wang; Jingui Sun; Jinping Dong; Guohua Yu; Zhiqin Gao; Bo Zhang; Guixiang Tian
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.